10-K Filing

INSIGHT MOLECULAR DIAGNOSTICS INC. CIK: 1642380 FY 2021

Filing Information

Form Type	10-K
Accession Number	`0001493152-22-006677`
Period End Date	20211231
Filing Date	20220311
Fiscal Year	2021
Fiscal Period	FY
XBRL Instance	form10-k_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 82 Income Statement 134 Cash Flow Statement 119 Stockholders Equity 36 Comprehensive Income 15

Balance Sheet 82 line items

Line Item	Tag	Value	Unit	Period
Preferred stock no par value	`PreferredStockNoParValue`	-	USD	Point-in-time
Preferred stock no par value	`PreferredStockNoParValue`	-	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$35.60M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$7.14M	USD	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Accounts receivable	`AccountsReceivableNetCurrent`	$203.00K	USD	Point-in-time
Accounts receivable	`AccountsReceivableNetCurrent`	$1.44M	USD	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Marketable equity securities	`EquitySecuritiesFvNi`	$904.00K	USD	Point-in-time
Common stock, no par value	`CommonStockNoParValue`	-	USD	Point-in-time
Common stock, no par value	`CommonStockNoParValue`	-	USD	Point-in-time
Marketable equity securities	`EquitySecuritiesFvNi`	$675.00K	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	230.00M	shares	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$1.20M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$1.21M	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	230.00M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$39.14M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	92.23M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	69.12M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$9.23M	USD	Point-in-time
Common stock, shares, outstanding	`CommonStockSharesOutstanding`	69.12M	shares	Point-in-time
Common stock, shares, outstanding	`CommonStockSharesOutstanding`	92.23M	shares	Point-in-time
Right-of-use and financing lease assets, net	`FinanceLeaseRightOfUseAsset`	$3.26M	USD	Point-in-time
Right-of-use and financing lease assets, net	`FinanceLeaseRightOfUseAsset`	$2.78M	USD	Point-in-time
Machinery and equipment, net, and construction in progress	`MachineryAndEquipmentNetAndConstructionInProgress`	$3.26M	USD	Point-in-time
Machinery and equipment, net, and construction in progress	`MachineryAndEquipmentNetAndConstructionInProgress`	$5.75M	USD	Point-in-time
Equity method investment in Razor	`EquityMethodInvestments`	-	USD	Point-in-time
Equity method investment in Razor	`EquityMethodInvestments`	$13.42M	USD	Point-in-time
Goodwill	`Goodwill`	$9.19M	USD	Point-in-time
Goodwill	`Goodwill`	$9.49M	USD	Point-in-time
Goodwill	`Goodwill`	$18.68M	USD	Point-in-time
Goodwill	`Goodwill`	$9.19M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$91.25M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$15.01M	USD	Point-in-time
Restricted cash	`RestrictedCashNoncurrent`	$1.70M	USD	Point-in-time
Restricted cash	`RestrictedCashNoncurrent`	$1.70M	USD	Point-in-time
Other noncurrent assets	`OtherAssetsNoncurrent`	$356.00K	USD	Point-in-time
Other noncurrent assets	`OtherAssetsNoncurrent`	$264.00K	USD	Point-in-time
TOTAL ASSETS	`Assets`	$55.42M	USD	Point-in-time
TOTAL ASSETS	`Assets`	$159.56M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$2.45M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$432.00K	USD	Point-in-time
Accrued compensation	`AccruedLiabilitiesCurrent`	$3.38M	USD	Point-in-time
Accrued compensation	`AccruedLiabilitiesCurrent`	$3.47M	USD	Point-in-time
Accrued expenses and other current liabilities	`AccountsPayableAndOtherAccruedLiabilitiesCurrent`	$2.28M	USD	Point-in-time
Accrued expenses and other current liabilities	`AccountsPayableAndOtherAccruedLiabilitiesCurrent`	$2.42M	USD	Point-in-time
Accrued severance from acquisition, current	`AccruedSeveranceFromAcquisitionCurrent`	-	USD	Point-in-time
Accrued severance from acquisition, current	`AccruedSeveranceFromAcquisitionCurrent`	$2.35M	USD	Point-in-time
Accrued liabilities from acquisition, current	`BusinessCombinationContingentConsiderationLiabilityCurrent`	$1.39M	USD	Point-in-time
Accrued liabilities from acquisition, current	`BusinessCombinationContingentConsiderationLiabilityCurrent`	-	USD	Point-in-time
Loans payable, net of deferred financing costs, current	`LoansPayableCurrent`	$2.39M	USD	Point-in-time
Loans payable, net of deferred financing costs, current	`LoansPayableCurrent`	$1.31M	USD	Point-in-time
Right-of-use and financing lease liabilities, current	`OperatingLeaseAndFinancingLeaseLiabilitiesCurrent`	$819.00K	USD	Point-in-time
Right-of-use and financing lease liabilities, current	`OperatingLeaseAndFinancingLeaseLiabilitiesCurrent`	$422.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$9.00M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$14.12M	USD	Point-in-time
Loans payable, net of deferred financing costs, noncurrent	`LongTermLoansPayable`	-	USD	Point-in-time
Loans payable, net of deferred financing costs, noncurrent	`LongTermLoansPayable`	$1.51M	USD	Point-in-time
Right-of-use and financing lease liabilities, noncurrent	`OperatingLeaseLiabilitiesAndFinancingLeaseLiabilitiesNonCurrent`	$4.31M	USD	Point-in-time
Right-of-use and financing lease liabilities, noncurrent	`OperatingLeaseLiabilitiesAndFinancingLeaseLiabilitiesNonCurrent`	$3.54M	USD	Point-in-time
Contingent consideration liabilities, noncurrent	`BusinessCombinationContingentConsiderationLiabilityNoncurrent`	$76.68M	USD	Point-in-time
Contingent consideration liabilities, noncurrent	`BusinessCombinationContingentConsiderationLiabilityNoncurrent`	$7.12M	USD	Point-in-time
TOTAL LIABILITIES	`Liabilities`	$21.94M	USD	Point-in-time
TOTAL LIABILITIES	`Liabilities`	$94.35M	USD	Point-in-time
Commitments and contingencies (Note 10)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Preferred stock, no par value, 5,000 shares authorized; no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock, no par value, 5,000 shares authorized; no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Common stock, no par value, 230,000 shares authorized; 92,232 and 69,117 shares issued and outstanding at December 31, 2021 and December 31, 2020, respectively	`CommonStockValue`	$157.16M	USD	Point-in-time
Common stock, no par value, 230,000 shares authorized; 92,232 and 69,117 shares issued and outstanding at December 31, 2021 and December 31, 2020, respectively	`CommonStockValue`	$252.95M	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$37.00K	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	-	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-123.68M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-187.77M	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$65.22M	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$33.48M	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$30.84M	USD	Point-in-time
TOTAL LIABILITIES AND SHAREHOLDERS EQUITY	`LiabilitiesAndStockholdersEquity`	$159.56M	USD	Point-in-time
TOTAL LIABILITIES AND SHAREHOLDERS EQUITY	`LiabilitiesAndStockholdersEquity`	$55.42M	USD	Point-in-time

Income Statement 134 line items

Line Item	Tag	Value	Unit	Period
Net revenue	`RevenueFromContractWithCustomerExcludingAssessedTax`	$503.00K	USD	1 Quarter
Net revenue	`RevenueFromContractWithCustomerExcludingAssessedTax`	$16.00K	USD	1 Quarter
Net revenue	`RevenueFromContractWithCustomerExcludingAssessedTax`	$143.00K	USD	1 Quarter
Net revenue	`RevenueFromContractWithCustomerExcludingAssessedTax`	$555.00K	USD	1 Quarter
Net revenue	`RevenueFromContractWithCustomerExcludingAssessedTax`	$3.59M	USD	1 Quarter
Net revenue	`RevenueFromContractWithCustomerExcludingAssessedTax`	$2.03M	USD	1 Quarter
Net revenue	`RevenueFromContractWithCustomerExcludingAssessedTax`	$1.12M	USD	1 Quarter
Net revenue	`RevenueFromContractWithCustomerExcludingAssessedTax`	$7.73M	USD	Annual
Net revenue	`RevenueFromContractWithCustomerExcludingAssessedTax`	$1.22M	USD	Annual
Net revenue	`RevenueFromContractWithCustomerExcludingAssessedTax`	$984.00K	USD	1 Quarter
Cost of revenues	`CostOfRevenue`	$716.00K	USD	1 Quarter
Cost of revenues	`CostOfRevenue`	$1.04M	USD	1 Quarter
Cost of revenues	`CostOfRevenue`	$173.00K	USD	1 Quarter
Cost of revenues	`CostOfRevenue`	$365.00K	USD	1 Quarter
Cost of revenues	`CostOfRevenue`	$1.85M	USD	1 Quarter
Cost of revenues	`CostOfRevenue`	$2.22M	USD	1 Quarter
Cost of revenues	`CostOfRevenue`	$2.42M	USD	1 Quarter
Cost of revenues	`CostOfRevenue`	$601.00K	USD	1 Quarter
Cost of revenues	`CostOfRevenue`	$4.18M	USD	Annual
Cost of revenues	`CostOfRevenue`	$1.85M	USD	Annual
Cost of revenues amortization of acquired intangibles	`CostOfRevenuesAmortizationOfAcquiredIntangibles`	$3.35M	USD	Annual
Cost of revenues amortization of acquired intangibles	`CostOfRevenuesAmortizationOfAcquiredIntangibles`	-	USD	Annual
Gross profit	`GrossProfit`	$188.00K	USD	Annual
Gross profit	`GrossProfit`	$-639.00K	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$9.80M	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$2.54M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$1.80M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$2.62M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$3.14M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$13.63M	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$3.36M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$3.23M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$125.00K	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$2.16M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$4.59M	USD	1 Quarter
Sales and marketing	`SellingAndMarketingExpense`	$2.25M	USD	1 Quarter
Sales and marketing	`SellingAndMarketingExpense`	$2.93M	USD	1 Quarter
Sales and marketing	`SellingAndMarketingExpense`	$6.49M	USD	Annual
Sales and marketing	`SellingAndMarketingExpense`	$1.57M	USD	1 Quarter
Sales and marketing	`SellingAndMarketingExpense`	$2.67M	USD	1 Quarter
Sales and marketing	`SellingAndMarketingExpense`	$1.56M	USD	1 Quarter
Sales and marketing	`SellingAndMarketingExpense`	$11.17M	USD	Annual
Sales and marketing	`SellingAndMarketingExpense`	$1.87M	USD	1 Quarter
Sales and marketing	`SellingAndMarketingExpense`	$1.49M	USD	1 Quarter
Sales and marketing	`SellingAndMarketingExpense`	$3.31M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	-	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$22.34M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$4.14M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$3.76M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$5.50M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$4.76M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$5.00M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$7.93M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$3.41M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$16.79M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$4.62M	USD	1 Quarter
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$1.17M	USD	1 Quarter
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$-4.01M	USD	Annual
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$-1.03M	USD	1 Quarter
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	-	USD	1 Quarter
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	-	USD	1 Quarter
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$27.27M	USD	Annual
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$1.06M	USD	1 Quarter
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$-2.98M	USD	1 Quarter
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$25.01M	USD	1 Quarter
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$30.00K	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$74.40M	USD	Annual
Total operating expenses	`OperatingExpenses`	$29.07M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-74.21M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-35.68M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-6.24M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-29.71M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-8.43M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-6.27M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-11.36M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-13.60M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-125.00K	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-13.57M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-8.77M	USD	1 Quarter
Interest expense, net	`InterestIncomeExpenseNet`	$-209.00K	USD	Annual
Interest expense, net	`InterestIncomeExpenseNet`	$-252.00K	USD	Annual
Unrealized gain (loss) on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$297.00K	USD	Annual
Unrealized gain (loss) on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$229.00K	USD	Annual
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	$-270.00K	USD	Annual
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	$-1.55M	USD	Annual
Gain on extinguishment of debt (PPP loan)	`GainsLossesOnExtinguishmentOfDebt`	$1.14M	USD	Annual
Gain on extinguishment of debt (PPP loan)	`GainsLossesOnExtinguishmentOfDebt`	-	USD	Annual
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$-37.00K	USD	Annual
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$27.00K	USD	Annual
Total other income (expenses), net	`NonoperatingIncomeExpense`	$-1.48M	USD	Annual
Total other income (expenses), net	`NonoperatingIncomeExpense`	$854.00K	USD	Annual
Total other income (expenses), net	`NonoperatingIncomeExpense`	$-340.00K	USD	1 Quarter
Total other income (expenses), net	`NonoperatingIncomeExpense`	$-539.00K	USD	1 Quarter
Total other income (expenses), net	`NonoperatingIncomeExpense`	$1.28M	USD	1 Quarter
Total other income (expenses), net	`NonoperatingIncomeExpense`	$-123.00K	USD	1 Quarter
Total other income (expenses), net	`NonoperatingIncomeExpense`	$-396.00K	USD	1 Quarter
Total other income (expenses), net	`NonoperatingIncomeExpense`	$-196.00K	USD	1 Quarter
Total other income (expenses), net	`NonoperatingIncomeExpense`	$-201.00K	USD	1 Quarter
Total other income (expenses), net	`NonoperatingIncomeExpense`	$-108.00K	USD	1 Quarter
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-9.11M	USD	1 Quarter
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-8.83M	USD	1 Quarter
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-13.80M	USD	1 Quarter
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-73.36M	USD	Annual
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-31.19M	USD	Annual
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-35.79M	USD	1 Quarter
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-6.47M	USD	1 Quarter
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-6.78M	USD	1 Quarter
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-11.48M	USD	1 Quarter
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-12.29M	USD	1 Quarter
Income tax benefit	`IncomeTaxExpenseBenefit`	$159.00K	USD	1 Quarter
Income tax benefit	`IncomeTaxExpenseBenefit`	-	USD	1 Quarter
Income tax benefit	`IncomeTaxExpenseBenefit`	-	USD	1 Quarter
Income tax benefit	`IncomeTaxExpenseBenefit`	-	USD	1 Quarter
Income tax benefit	`IncomeTaxExpenseBenefit`	$1.09M	USD	1 Quarter
Income tax benefit	`IncomeTaxExpenseBenefit`	$7.56M	USD	1 Quarter
Income tax benefit	`IncomeTaxExpenseBenefit`	$-97.00K	USD	1 Quarter
Income tax benefit	`IncomeTaxExpenseBenefit`	$-1.25M	USD	Annual
Income tax benefit	`IncomeTaxExpenseBenefit`	$-9.26M	USD	Annual
Income tax benefit	`IncomeTaxExpenseBenefit`	$1.79M	USD	1 Quarter
NET LOSS	`NetIncomeLoss`	$-13.80M	USD	1 Quarter
NET LOSS	`NetIncomeLoss`	$-125.00K	USD	1 Quarter
NET LOSS	`NetIncomeLoss`	$-10.49M	USD	1 Quarter
NET LOSS	`NetIncomeLoss`	$-35.88M	USD	1 Quarter
NET LOSS	`NetIncomeLoss`	$-6.31M	USD	1 Quarter
NET LOSS	`NetIncomeLoss`	$-64.10M	USD	Annual
NET LOSS	`NetIncomeLoss`	$-29.93M	USD	Annual
NET LOSS	`NetIncomeLoss`	$-6.78M	USD	1 Quarter
NET LOSS	`NetIncomeLoss`	$-3.92M	USD	1 Quarter
NET LOSS	`NetIncomeLoss`	$-9.11M	USD	1 Quarter
NET LOSS	`NetIncomeLoss`	$-7.73M	USD	1 Quarter
Net loss per share: basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.46	USD	Annual
Net loss per share: basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.72	USD	Annual
Weighted average shares outstanding: basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	65,478.00	shares	Annual
Weighted average shares outstanding: basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	88,920.00	shares	Annual

Cash Flow Statement 119 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-13.80M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-125.00K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-10.49M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-35.88M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-6.31M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-64.10M	USD	Annual
Net loss	`NetIncomeLoss`	$-29.93M	USD	Annual
Net loss	`NetIncomeLoss`	$-6.78M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-3.92M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-9.11M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-7.73M	USD	1 Quarter
Depreciation expense	`Depreciation`	$313.00K	USD	Annual
Depreciation expense	`Depreciation`	$844.00K	USD	Annual
Amortization of intangible assets	`AmortizationOfIntangibleAssets`	$3.36M	USD	Annual
Amortization of intangible assets	`AmortizationOfIntangibleAssets`	$81.00K	USD	Annual
Impairment charge for long-lived assets	`ImpairmentOfLongLivedAssetsToBeDisposedOf`	$422.00K	USD	Annual
Impairment charge for long-lived assets	`ImpairmentOfLongLivedAssetsToBeDisposedOf`	-	USD	Annual
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	$-270.00K	USD	Annual
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	$-1.55M	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$6.84M	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$5.07M	USD	Annual
Unrealized gain on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$297.00K	USD	Annual
Unrealized gain on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$229.00K	USD	Annual
Amortization of debt issuance costs	`AmortizationOfFinancingCosts`	$102.00K	USD	Annual
Amortization of debt issuance costs	`AmortizationOfFinancingCosts`	$56.00K	USD	Annual
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$1.17M	USD	1 Quarter
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$-4.01M	USD	Annual
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$-1.03M	USD	1 Quarter
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	-	USD	1 Quarter
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	-	USD	1 Quarter
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$27.27M	USD	Annual
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$1.06M	USD	1 Quarter
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$-2.98M	USD	1 Quarter
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$25.01M	USD	1 Quarter
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$30.00K	USD	1 Quarter
Deferred income tax benefit	`DeferredIncomeTaxExpenseBenefit`	$-1.25M	USD	Annual
Deferred income tax benefit	`DeferredIncomeTaxExpenseBenefit`	$-9.26M	USD	Annual
Gain on extinguishment of debt (PPP loan)	`GainsLossesOnExtinguishmentOfDebt`	$1.14M	USD	Annual
Gain on extinguishment of debt (PPP loan)	`GainsLossesOnExtinguishmentOfDebt`	-	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$182.00K	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$1.23M	USD	Annual
Lease liabilities	`IncreaseDecreaseInOperatingLeaseLiability`	$147.00K	USD	Annual
Lease liabilities	`IncreaseDecreaseInOperatingLeaseLiability`	$1.50M	USD	Annual
Prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-227.00K	USD	Annual
Prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$188.00K	USD	Annual
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$848.00K	USD	Annual
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-1.35M	USD	Annual
Accrued severance from Chronix Biomedical acquisition	`AccruedSeveranceFromChronixBiomedicalAcquisition`	-	USD	Annual
Accrued severance from Chronix Biomedical acquisition	`AccruedSeveranceFromChronixBiomedicalAcquisition`	$2.35M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-25.98M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-35.94M	USD	Annual
Acquisition of Insight Genetics, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$607.00K	USD	Annual
Acquisition of Insight Genetics, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$6.19M	USD	Annual
Acquisition of Razor Genomics asset, net of cash acquired	`AcquisitionOfRazorGenomicsAssetNetOfCashAcquired`	-	USD	Annual
Acquisition of Razor Genomics asset, net of cash acquired	`AcquisitionOfRazorGenomicsAssetNetOfCashAcquired`	$6.65M	USD	Annual
Acquisition of Chronix Biomedical, net of cash acquired	`AcquisitionOfChronixBiomedicalNetOfCashAcquired`	$325.00K	USD	Annual
Acquisition of Chronix Biomedical, net of cash acquired	`AcquisitionOfChronixBiomedicalNetOfCashAcquired`	$4.46M	USD	Annual
Equity method investment in Razor	`PaymentsToAcquireEquityMethodInvestments`	-	USD	Annual
Equity method investment in Razor	`PaymentsToAcquireEquityMethodInvestments`	$4.00M	USD	Annual
Construction in progress and purchases of furniture and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$2.25M	USD	Annual
Construction in progress and purchases of furniture and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$1.23M	USD	Annual
Security deposit and other	`ProceedsFromSecurityDepositAndOther`	$-7.00K	USD	Annual
Security deposit and other	`ProceedsFromSecurityDepositAndOther`	-	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-11.75M	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-13.96M	USD	Annual
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$2.58M	USD	Annual
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$1.45M	USD	Annual
Proceeds from sale of common shares	`ProceedsFromIssuanceOfCommonStock`	$65.26M	USD	Annual
Proceeds from sale of common shares	`ProceedsFromIssuanceOfCommonStock`	$18.34M	USD	Annual
Financing costs to issue common shares	`PaymentsOfStockIssuanceCosts`	$2.67M	USD	Annual
Financing costs to issue common shares	`PaymentsOfStockIssuanceCosts`	$58.00K	USD	Annual
Proceeds from sale of common shares under at-the-market transactions	`ProceedsFromIssuanceOfPrivatePlacement`	$2.46M	USD	Annual
Proceeds from sale of common shares under at-the-market transactions	`ProceedsFromIssuanceOfPrivatePlacement`	$12.72M	USD	Annual
Financing costs for at-the-market sales	`PaymentForFinancingCostsForAtthemarketSales`	$74.00K	USD	Annual
Financing costs for at-the-market sales	`PaymentForFinancingCostsForAtthemarketSales`	$390.00K	USD	Annual
Proceeds from exercise of warrants	`ProceedsFromWarrantExercises`	$2.63M	USD	Annual
Proceeds from exercise of warrants	`ProceedsFromWarrantExercises`	-	USD	Annual
Common shares received and retired for employee taxes paid	`CommonSharesReceivedAndRetiredForEmployeeTaxesPaid`	$239.00K	USD	Annual
Common shares received and retired for employee taxes paid	`CommonSharesReceivedAndRetiredForEmployeeTaxesPaid`	$14.00K	USD	Annual
Repayment of loan payable	`RepaymentsOfDebt`	$1.50M	USD	Annual
Repayment of loan payable	`RepaymentsOfDebt`	$375.00K	USD	Annual
Repayment of financing lease obligations	`RepaymentOfFinancingLeaseObligations`	$34.00K	USD	Annual
Repayment of financing lease obligations	`RepaymentOfFinancingLeaseObligations`	$71.00K	USD	Annual
Proceeds from PPP loan	`ProceedsFromIssuanceOfLongTermDebt`	$1.14M	USD	Annual
Proceeds from PPP loan	`ProceedsFromIssuanceOfLongTermDebt`	-	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$22.80M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$78.36M	USD	Annual
NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-14.93M	USD	Annual
NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$28.46M	USD	Annual
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$8.84M	USD	Point-in-time
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$37.30M	USD	Point-in-time
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$23.77M	USD	Point-in-time
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$8.84M	USD	Point-in-time
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$37.30M	USD	Point-in-time
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$23.77M	USD	Point-in-time
Cash paid for interest	`InterestPaidNet`	$209.00K	USD	Annual
Cash paid for interest	`InterestPaidNet`	$114.00K	USD	Annual
Common stock issued for acquisition of Razor Genomics assets	`CommonStockIssuedForAcquisition`	$5.76M	USD	Annual
Common stock issued for acquisition of Razor Genomics assets	`CommonStockIssuedForAcquisition`	-	USD	Annual
Deferred tax liability generated from the acquisition of Razor Genomics assets	`DeferredTaxLiabilityGeneratedFromAcquisitionOfRazorGenomicsAsset`	-	USD	Annual
Deferred tax liability generated from the acquisition of Razor Genomics assets	`DeferredTaxLiabilityGeneratedFromAcquisitionOfRazorGenomicsAsset`	$7.08M	USD	Annual
Common stock issued for acquisition of Insight Genetics	`CommonStockIssuedForAcquisitionOfInsightGenetics`	$5.00M	USD	Annual
Common stock issued for acquisition of Insight Genetics	`CommonStockIssuedForAcquisitionOfInsightGenetics`	-	USD	Annual
Common stock issued for acquisition of Chronix Biomedical	`CommonStockIssuedForAcquisitionOfChronixBiomedical`	-	USD	Annual
Common stock issued for acquisition of Chronix Biomedical	`CommonStockIssuedForAcquisitionOfChronixBiomedical`	$3.30M	USD	Annual
Deferred tax liability generated from the acquisition of Chronix	`DeferredTaxLiabilityGeneratedFromAcquisitionOfChronix`	-	USD	Annual
Deferred tax liability generated from the acquisition of Chronix	`DeferredTaxLiabilityGeneratedFromAcquisitionOfChronix`	$2.18M	USD	Annual
Initial fair value of contingent consideration at acquisition date	`InitialFairValueOfContingentConsiderationAtAcquisitionDate`	$42.30M	USD	Annual
Initial fair value of contingent consideration at acquisition date	`InitialFairValueOfContingentConsiderationAtAcquisitionDate`	$11.13M	USD	Annual
Assumed liability from Chronix Acquisition	`AssumedLiabilityFromChronixAcquisition`	-	USD	Annual
Assumed liability from Chronix Acquisition	`AssumedLiabilityFromChronixAcquisition`	$3.35M	USD	Annual
Holdback liability	`HoldbackLiability`	$600.00K	USD	Annual
Holdback liability	`HoldbackLiability`	-	USD	Annual
Construction in progress, machinery and equipment purchases included in accounts payable, accrued liabilities and landlord liability	`ConstructionInProgressMachineryAndEquipmentPurchasesIncludedInAccountsPayableAccruedliabilitiesAndLandlordLiability`	$1.08M	USD	Annual
Construction in progress, machinery and equipment purchases included in accounts payable, accrued liabilities and landlord liability	`ConstructionInProgressMachineryAndEquipmentPurchasesIncludedInAccountsPayableAccruedliabilitiesAndLandlordLiability`	$2.05M	USD	Annual
Accounts receivable from agent for at-the-market sales of common stock, net of financing costs	`AccountsReceivableFromAgentForAtthemarketSalesOfCommonStockNetOfFinancingCosts`	-	USD	Annual
Accounts receivable from agent for at-the-market sales of common stock, net of financing costs	`AccountsReceivableFromAgentForAtthemarketSalesOfCommonStockNetOfFinancingCosts`	$262.00K	USD	Annual
Issuance of common stock in lieu of cash for payment of board fees and deferred salaries	`StockIssued1`	-	USD	Annual
Issuance of common stock in lieu of cash for payment of board fees and deferred salaries	`StockIssued1`	$169.00K	USD	Annual

Stockholders Equity 36 line items

Line Item	Tag	Value	Unit	Period
Balance	`StockholdersEquity`	$65.22M	USD	Point-in-time
Balance	`StockholdersEquity`	$33.48M	USD	Point-in-time
Balance	`StockholdersEquity`	$30.84M	USD	Point-in-time
Net Loss	`NetIncomeLoss`	$-13.80M	USD	1 Quarter
Net Loss	`NetIncomeLoss`	$-125.00K	USD	1 Quarter
Net Loss	`NetIncomeLoss`	$-10.49M	USD	1 Quarter
Net Loss	`NetIncomeLoss`	$-35.88M	USD	1 Quarter
Net Loss	`NetIncomeLoss`	$-6.31M	USD	1 Quarter
Net Loss	`NetIncomeLoss`	$-64.10M	USD	Annual
Net Loss	`NetIncomeLoss`	$-29.93M	USD	Annual
Net Loss	`NetIncomeLoss`	$-6.78M	USD	1 Quarter
Net Loss	`NetIncomeLoss`	$-3.92M	USD	1 Quarter
Net Loss	`NetIncomeLoss`	$-9.11M	USD	1 Quarter
Net Loss	`NetIncomeLoss`	$-7.73M	USD	1 Quarter
Stock-based compensation	`StockIssuedDuringPeriodValueShareBasedCompensationGross`	$6.84M	USD	Annual
Stock-based compensation	`StockIssuedDuringPeriodValueShareBasedCompensationGross`	$5.07M	USD	Annual
Sale of common shares	`StockIssuedDuringPeriodValueNewIssues`	$18.34M	USD	Annual
Financing costs paid to issue common shares, including at-the-market transactions	`StockIssuedDuringPeriodValueOther`	$-58.00K	USD	Annual
Financing costs paid to issue common shares, including at-the-market transactions	`StockIssuedDuringPeriodValueOther`	$-3.06M	USD	Annual
Sale of common shares, including at-the-market transactions	`StockIssuedDuringPeriodValueOfSaleOfCommonSharesUnderAtthemarketTransactions`	$2.73M	USD	Annual
Sale of common shares, including at-the-market transactions	`StockIssuedDuringPeriodValueOfSaleOfCommonSharesUnderAtthemarketTransactions`	$77.99M	USD	Annual
Financing costs for at-the-market transactions	`StockIssuedDuringPeriodValueFinancingCostsForAtthemarketTransactions`	$-82.00K	USD	Annual
Stock options exercised	`StockIssuedDuringPeriodValueStockOptionsExercised`	$2.58M	USD	Annual
Stock options exercised	`StockIssuedDuringPeriodValueStockOptionsExercised`	$1.42M	USD	Annual
Stock options exercised, shares	`StockIssuedDuringPeriodSharesStockOptionsExercised`	924,000.00	shares	Annual
Warrants exercised	`StockIssuedDuringPeriodValueWarrantsExercised`	$2.63M	USD	Annual
Shares issued upon vesting of RSU, net of shares retired to pay employees taxes	`SharesIssuedUponVestingOfRsuNetOfSharesRetiredToPayEmployeesTaxes`	$-15.00K	USD	Annual
Shares issued upon vesting of RSU, net of shares retired to pay employees taxes	`SharesIssuedUponVestingOfRsuNetOfSharesRetiredToPayEmployeesTaxes`	$-239.00K	USD	Annual
Issuance of common stock in lieu of cash for payment of board fees and deferred salaries	`StockIssuedDuringPeriodValueIssuedForServices`	$169.00K	USD	Annual
Issuance of common stock as partial consideration for Insight Genetics, Inc. acquisition	`StockIssuedDuringPeriodValueAcquisitions`	$5.00M	USD	Annual
Issuance of common stock as consideration for Razor Genomics acquisition	`StockIssuedDuringPeriodValueAcquisitionsOne`	$5.76M	USD	Annual
Issuance of common stock as consideration for Chronix Biomedical acquisition	`StockIssuedDuringPeriodValueAcquisitionsTwo`	$3.30M	USD	Annual
Foreign currency translation adjustment	`AdjustmentstoForeignCurrencyTranslation`	$37.00K	USD	Annual
Balance	`StockholdersEquity`	$65.22M	USD	Point-in-time
Balance	`StockholdersEquity`	$33.48M	USD	Point-in-time
Balance	`StockholdersEquity`	$30.84M	USD	Point-in-time

Comprehensive Income 15 line items

Line Item	Tag	Value	Unit	Period
NET LOSS	`NetIncomeLoss`	$-13.80M	USD	1 Quarter
NET LOSS	`NetIncomeLoss`	$-125.00K	USD	1 Quarter
NET LOSS	`NetIncomeLoss`	$-10.49M	USD	1 Quarter
NET LOSS	`NetIncomeLoss`	$-35.88M	USD	1 Quarter
NET LOSS	`NetIncomeLoss`	$-6.31M	USD	1 Quarter
NET LOSS	`NetIncomeLoss`	$-64.10M	USD	Annual
NET LOSS	`NetIncomeLoss`	$-29.93M	USD	Annual
NET LOSS	`NetIncomeLoss`	$-6.78M	USD	1 Quarter
NET LOSS	`NetIncomeLoss`	$-3.92M	USD	1 Quarter
NET LOSS	`NetIncomeLoss`	$-9.11M	USD	1 Quarter
NET LOSS	`NetIncomeLoss`	$-7.73M	USD	1 Quarter
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$37.00K	USD	Annual
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	-	USD	Annual
COMPREHENSIVE LOSS	`ComprehensiveIncomeNetOfTax`	$-29.93M	USD	Annual
COMPREHENSIVE LOSS	`ComprehensiveIncomeNetOfTax`	$-64.06M	USD	Annual

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.